文献速递消化系统肿瘤

曲氟尿苷替匹嘧啶对比安慰剂治疗经治转移性胃癌的III期TAGS试验

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2018-10-21

TAGS是一项随机双盲安慰剂对照III期试验,在17个国家110家学术医院纳入507例至少接受过两线化疗后进展的转移性胃腺癌患者,按2:1随机接受曲氟尿苷替匹嘧啶(35 mg/m2,每日两次,第1-5天和第8-12天,每28天)或安慰剂,均联合最佳支持治疗。

要点

  • ≥3级不良事件发生率曲氟尿苷替匹嘧啶组80%,安慰剂组58%,常见为中性粒细胞减少和贫血。
  • 曲氟尿苷替匹嘧啶可作为重度经治晚期胃癌患者的新治疗选择。

核心结论

  • 在重度经治的晚期胃癌患者中,曲氟尿苷替匹嘧啶较安慰剂显著改善总生存期且耐受性良好。

研究设计与样本

  • TAGS为随机、双盲、安慰剂对照III期试验,在17个国家110家学术医院开展。
  • 纳入507例至少接受过两线化疗后影像学进展的转移性胃腺癌(含胃食管结合部腺癌)患者,按2:1随机分配至曲氟尿苷替匹嘧啶组(337例)或安慰剂组(170例),均联合最佳支持治疗。
  • 随机分层因素为地区(日本 vs 世界其他地区)、ECOG体能状态(0 vs 1)和既往雷莫芦单抗治疗(是 vs 否)。
  • 主要终点为总生存期,在意向治疗人群中评估疗效,在至少接受一剂治疗的患者中评估安全性。

主要发现

  • 曲氟尿苷替匹嘧啶组≥3级任何原因不良事件发生率为80%(267例),安慰剂组为58%(97例)。
  • 曲氟尿苷替匹嘧啶组最常见的≥3级任何原因不良事件为中性粒细胞减少(114例[34%])和贫血(64例[19%]);安慰剂组为腹痛(15例[9%])和一般身体健康状况恶化(15例[9%])。
  • 曲氟尿苷替匹嘧啶组严重不良事件发生率为43%(143例),安慰剂组为42%(70例);每组各报告1例治疗相关死亡(曲氟尿苷替匹嘧啶组为心脏骤停,安慰剂组为中毒性肝炎)。

关键数值与推荐

  • 曲氟尿苷替匹嘧啶用法:口服35 mg/m2,每日两次,第1-5天和第8-12天,每28天重复。
  • 入组标准:年龄≥18岁,组织学确诊的不可切除转移性胃腺癌(包括胃食管结合部腺癌),AJCC第7版分期,至少接受过两线化疗且影像学进展。

临床怎么用

  • 对于至少两线化疗后进展的转移性胃腺癌患者,可考虑使用曲氟尿苷替匹嘧啶联合最佳支持治疗。
  • 治疗期间需重点监测中性粒细胞减少和贫血等血液学毒性。

局限性

  • 原文未报告无进展生存期、客观缓解率等次要终点数据。
  • 原文未报告生活质量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trifluridine/tipiracil showed activity and was well tolerated in a phase 2 study of pretreated patients with advanced gastric cancer done in Japan. We investigated whether the treatment was efficacious compared with placebo in a global population. METHODS: TAGS was a randomised, double-blind, placebo-controlled, phase 3 trial done in 110 academic hospitals in 17 countries. Patients aged 18 years or older with histologically confirmed, non-resectable, metastatic gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction) as defined by the American Joint Committee on Cancer staging classification (7th edition) who had received at least two previous chemotherapy regimens and had experienced radiological disease progression were eligible for inclusion. Patients were randomly assigned (2:1) via dynamic randomisation from a centralised interactive voice-response system to receive either oral trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 days) plus best supportive care or placebo plus best supportive care. Participants were allocated to groups by study-site personnel. Randomisation was stratified by region (Japan vs rest of world), ECOG performance status (0 vs 1), and previous treatment with ramucirumab (yes vs no). Both patients and investigators were masked to treatment allocation. The primary endpoint was overall survival. Efficacy was assessed in the intention-to-treat population and safety in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, number NCT02500043. The trial, including follow-up of all participants, has been completed. FINDINGS: Between Feb 24, 2016, and Jan 5, 2018, 507 patients were enrolled and randomly assigned, 337 to the trifluridine/tipiracil group and 170 to the placebo group. Median overall survival was 5·7 months (95% CI 4·8-6·2) in the trifluridine/tipiracil group and 3·6 months (3·1-4·1) in the placebo group (hazard ratio 0·69 [95% CI 0·56-0·85]; one-sided p=0·00029, two-sided p=0·00058). Grade 3 or worse adverse events of any cause occurred in 267 (80%) patients in the trifluridine/tipiracil group and 97 (58%) in the placebo group. The most frequent grade 3 or worse adverse events of any cause were neutropenia (n=114 [34%]) and anaemia (n=64 [19%]) in the trifluridine/tipiracil group and abdominal pain (n=15 [9%]) and general deterioration of physical health (n=15 [9%]) in the placebo group. Serious adverse events of any cause were reported in 143 (43%) patients in the trifluridine/tipiracil group and 70 (42%) in the placebo group. One treatment-related death was reported in each group (because of cardiopulmonary arrest in the trifluridine/tipiracil group and because of toxic hepatitis in the placebo group). INTERPRETATION: Trifluridine/tipiracil significantly improved overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer. Trifluridine/tipiracil could be a new treatment option in this population who represent a high unmet medical need. FUNDING: Taiho Oncology and Taiho Pharmaceutical.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018. PMID: 30355453. doi:10.1016/S1470-2045(18)30739-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。